A look at the changing face of the RCC landscape, including current and near term trial readouts
As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?
A look at some new targeted and IO combinations in development for advanced prostate cancer
Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?
Highlights and Lowlights from ASCO GU 2018 - what to watch out for.
Interview with Dr Daniel George on Phase 3 PROSPER trial results
A look at where we are in pancreatic cancer and how the landscape has evolved of late...
A look at 8 key abstracts being presented at #GI18 in San Francisco this week.